Invest in iMBP - Learn more

iMetabolic Biopharma Corporation
  • Home
  • build the future
  • Discover our techbio
  • Meet the team
  • invest today
  • More
    • Home
    • build the future
    • Discover our techbio
    • Meet the team
    • invest today
iMetabolic Biopharma Corporation
  • Home
  • build the future
  • Discover our techbio
  • Meet the team
  • invest today

What is techbio?

We have developed a proprietary computational approach that uses in-silico therapeutic discovery and molecular design to improve upon traditional biotechnology. This makes up our iPlatform™ and this is TechBio, the future of biopharma.


This creates both economic and time-saving advantages to drug discovery, allowing for life-saving solutions to potentially reach the clinic faster and more affordably.


If you’ve ever wanted to invest in a biotechnology company, now is the time! 

invest today

Benefits of the iPlatform™

Revolutionary Versatility

Revolutionary Versatility

Revolutionary Versatility

Develops drugs with wide range applications

UnparallelED Precision

Revolutionary Versatility

Revolutionary Versatility

Delivers highly effective and functional treatments

Improved Risk Mitigation

Revolutionary Versatility

Improved Risk Mitigation

Creates safer drugs in less time at less cost

Partnership with Amazon Web Services


The development of iPlatform™ is supported in part through a partnership agreement  with Amazon Web Services (AWS) to aid in the development of its proprietary iPlatform™ technology.  

iPlatform™ Therapeutic Pipeline


 iMBP has five established disease therapeutic asset programs, with four additional programs in preparation to go online. We're also proud to announce our issued U.S. patent for proprietary therapeutic methodology (US/9,783,600).

partnership with Omniab & LIgand Pharmaceuticals

Our TechBio approach has allowed iMBP to achieve multiple milestones normally not experienced in BioTech companies until much later in life.


This has been significantly enabled through two partnership agreements with Ligand Pharmaceuticals/OmniAb for drug asset development.


“Ligand is proud of its heritage of establishing strategic partnerships with innovative, emerging organizations with experienced management teams, and our agreement with iMetabolic Biopharma Corporation is another example of such an alliance” 

                            John Higgins  - Former CEO at Ligand Pharmaceuticals


Join us!

By investing today, you’re giving communities the opportunity to invest in their own heath while improving the ways drugs are discovered. 

invest now

Copyright © 2023 iMetabolic Biopharma Corporation - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept